GLO Dutch Bidco / Mallinckrodt Netherlands and Mallinckrodt Nuclear Medicine merger inquiry

The CMA is investigating the completed acquisition by GLO Dutch Bidco of Mallinckrodt Netherlands Holdings BV and Mallinckrodt Nuclear Medicine LLC.

Statutory timetable

Phase 1 Date Action
TBC Deadline for phase 1 decision (*)
TBC Launch of merger inquiry
24 March 2017 Initial enforcement order

(*) This date is the current statutory deadline by when the decision will be announced. If any change occurs, the information is refreshed as soon as practicable. However, the CMA cannot guarantee that the decision will be announced on or before this current deadline, as the deadline of a given case may change during the merger assessment process due to different reasons.

Phase 1

Initial enforcement order

31 March 2017: On 24 March 2017, the CMA served an initial enforcement order under section 72(2) of the Enterprise Act 2002 on GLO BidCo S.ả r.l., IBA Pharma SA, GLO Dutch Bidco, B.V. and Mallinckrodt Netherlands Holdings BV, in relation to the completed acquisition GLO Dutch Bidco B.V. of Mallinckrodt Netherlands Holdings B.V. and Mallinckrodt Nuclear Medicine LLC.

Amendments/consents granted

Contact

Please send written representations about any competition or public interest to:

Daniella Sinobad
Competition and Markets Authority
Victoria House
Southampton Row
London
WC1B 4AD

daniella.sinobad@cma.gsi.gov.uk

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.